Tarceva Could Lock Down Market For First-Line Non-Small Cell Lung Cancer With EGFR Mutation
This article was originally published in The Pink Sheet Daily
Executive Summary
After positive EURTAC study, Genentech and OSI plan to talk to FDA about narrow first-line lung cancer indication and a companion diagnostic.